Amedica Releases New Interbody Fusion Device From Valeo Line

Salt Lake City, Utah-based Amedica Corp. has released its silicon nitride lateral lumbar (LL) interbody fusion device. The Valeo II LL interbody fusion device will be commercially available in mid-September, and will include second generation instrumentation to improve patient safety and surgeon ease of use.

“With the release of our new lateral system, we are now able to offer an additional lumbar solution to our line of second generation silicon nitride interbody devices,” said Sonny Bal, M.D., J.D., chairman and CEO of Amedica Corporation. “Initial feedback from our beta users has been positive and we’re very pleased to offer this lateral interbody fusion device system, which provides surgeons additional procedure options and allows Amedica access to one of the fastest growing segments in the lumbar fusion market.”

The Valeo II LL is made of a micro composite silicon nitride biomaterial, which is designed to offer a superior environment for bone growth and osteointegration when compared to competitive PEEK (polyetheretherketone) and titanium offerings. Amedica’s Valeo II silicon nitride interbody fusion devices also contain anti-infective properties and are semi-radiolucent with clearly visible boundaries in X-rays and produce no artifacts under MRI (magnetic resonance imaging) or CT (computed tomography) scans. The combination of these properties is found only in Amedica’s silicon nitride biomaterial technology.

The Valeo II LL is indicated for intervertebral body fusion of the spine in skeletally mature patients and is designed for use with autograft to facilitate fusion. The Valeo line of spine I plants are cleared by the U.S. Food and Drug Administration.